ストックスクリーナーアプリを入手
11.23
2.46%
0.27
前日終値:
$10.96
開ける：
$11.26
24時間の取引高:
11,921
Relative Volume:
0.09
時価総額：
$270.83M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+6.85%
1か月 パフォーマンス:
+7.16%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$10.74
$11.52
1週間の範囲:
$10.00
$11.57
52週間の値動き範囲:
$9.68
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
名前
Artiva Biotherapeutics Inc
セクター
電話
(858) 267-4467
住所
5505 MOREHOUSE DRIVE, SAN DIEGO
ARTV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ARTV | 11.31 | 270.83M | 0 | 0 | 0 | 0.00 |
| VRTX | 450.26 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.54 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.32 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.56 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 開始されました | Jefferies | Buy |
| 2024-08-13 | 開始されました | Needham | Buy |
| 2024-08-13 | 開始されました | TD Cowen | Buy |
| 2024-08-13 | 開始されました | Wedbush | Outperform |
Artiva Biotherapeutics Inc (ARTV) 最新ニュース
Cantor Fitzgerald Forecasts ARTV FY2024 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2024 Earnings - MarketBeat
Wedbush Has Bearish Estimate for ARTV FY2024 Earnings - Defense World
Wedbush Lowers Earnings Estimates for Artiva Biotherapeutics - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Issues Quarterly Earnings Results, Misses Estimates By $0.24 EPS - MarketBeat
Artiva Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC - MarketBeat
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference - The Manila Times
Artiva Bio to Present at Jefferies Healthcare Conference, Spotlight on Cell Therapy Pipeline | ARTV Stock News - StockTitan
Artiva Biotherapeutics (NASDAQ:ARTV) vs. Iovance Biotherapeutics (NASDAQ:IOVA) Critical Review - Defense World
Cell therapy developer Artiva refiles for a $100M IPO - MSN
Artiva Biotherapeutics appoints new board member By Investing.com - Investing.com Australia
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - ForexTV.com
Artiva Biotherapeutics, Inc. Appoints Alison Moore as an Independent Member of Its Board of Directors - Marketscreener.com
Artiva Biotherapeutics appoints new board member - Investing.com
Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4%Time to Sell? - MarketBeat
Wall Street SWOT: Artiva Biotherapeutics stockNK cell pioneer targets autoimmune market By Investing.com - Investing.com South Africa
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Artiva Biotherapeutics (NASDAQ:ARTV) Trading 6.2% Higher - MarketBeat
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Quiet Period Will End on August 28th - Defense World
Artiva Biotherapeutics, Inc.'s Quiet Period Set To Expire on August 28th (NASDAQ:ARTV) - MarketBeat
Brokers Issue Forecasts for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV) - MarketBeat
Analysts Set Expectations for Artiva Biotherapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Quotes, Forecast and News Summary - Benzinga
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch - Benzinga
Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at TD Cowen - Defense World
Needham & Company LLC Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Wedbush Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Cantor Fitzgerald - Defense World
Non-Hodgkin Lymphoma Drugs Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc - Barchart
July IPOs to Watch in Tech, Biotech, Food Security and Transportation - Investorideas.com newswire
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares - 24/7 Wall St.
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal - Seeking Alpha
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Yong-Jun Huh Buys 2,083,332 Shares - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Global Strategic Fund I. Venbio Purchases 416,666 Shares - Defense World
VenBio fund acquires $5m in Artiva Biotherapeutics stock By Investing.com - Investing.com Australia
VenBio fund acquires $5m in Artiva Biotherapeutics stock - Investing.com India
Artiva Biotherapeutics sees major stock purchases by GC Corp entities - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO By Investing.com - Investing.com South Africa
Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO - Investing.com India
Artiva Biotherapeutics Inc (ARTV) 財務データ
Artiva Biotherapeutics Inc (ARTV) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):